Cantor Fitzgerald analyst Louise Chen thinks FDA approval of Amgen’s (AMGN) Aimovig is positive for Teva (TEVA) as well as other new potential migraine treatments coming to the market because it underscores the large unmet need. She notes, however, that Teva does not expect approval until later this year given its manufacturing issues. The analyst keeps a Neutral rating on Teva with an $18 price target.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.